"Scleroderma, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Descriptor ID |
D012595
|
| MeSH Number(s) |
C17.300.799 C17.800.784
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Scleroderma, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Scleroderma, Systemic".
This graph shows the total number of publications written about "Scleroderma, Systemic" by people in this website by year, and whether "Scleroderma, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 8 | 0 | 8 |
| 2010 | 5 | 0 | 5 |
| 2011 | 9 | 0 | 9 |
| 2012 | 3 | 0 | 3 |
| 2013 | 4 | 0 | 4 |
| 2014 | 6 | 1 | 7 |
| 2015 | 2 | 0 | 2 |
| 2016 | 5 | 0 | 5 |
| 2017 | 4 | 0 | 4 |
| 2018 | 4 | 1 | 5 |
| 2019 | 7 | 1 | 8 |
| 2020 | 3 | 0 | 3 |
| 2021 | 3 | 0 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 6 | 0 | 6 |
| 2024 | 2 | 3 | 5 |
| 2025 | 4 | 0 | 4 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Scleroderma, Systemic" by people in Profiles.
-
The added value of cardiac MRI in paediatric rheumatologic disorders: a preliminary single-centre experience. Cardiol Young. 2026 Feb; 36(2):386-388.
-
International Investigation of the Gut-Lung Axis in Systemic Sclerosis-Interstitial Lung Disease. Arthritis Care Res (Hoboken). 2026 Mar; 78(3):352-361.
-
Racial and ethnic associations with interstitial lung disease and healthcare utilization in patients with systemic sclerosis. Rheumatology (Oxford). 2025 Dec 01; 64(SI):SI131-SI139.
-
Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohorts. Thorax. 2025 07 15; 80(8):540-546.
-
Integrative exome sequencing and machine learning identify MICB and interferon pathway genes as contributors to SSc risk. Ann Rheum Dis. 2025 Aug; 84(8):1363-1374.
-
Exploring the complexity of systemic sclerosis etiology by trio whole genome sequencing. Hum Mol Genet. 2024 09 19; 33(19):1643-1647.
-
PIK-III exerts anti-fibrotic effects in activated fibroblasts by regulating p38 activation. PLoS One. 2024; 19(9):e0306624.
-
Insights into the genetic landscape of systemic sclerosis. Best Pract Res Clin Rheumatol. 2024 12; 38(4):101981.
-
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024 Aug; 76(8):1201-1213.
-
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024 Aug; 76(8):1182-1200.